Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10.
Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, Fritz JL, Beck A, El-Deiry WS. Allen JE, et al. Among authors: talekar m. Cancer Res. 2015 Apr 15;75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356. Epub 2015 Feb 13. Cancer Res. 2015. PMID: 25681273 Free PMC article.
Targeting TRAIL in the treatment of cancer: new developments.
Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Lim B, et al. Expert Opin Ther Targets. 2015;19(9):1171-85. doi: 10.1517/14728222.2015.1049838. Epub 2015 May 25. Expert Opin Ther Targets. 2015. PMID: 26004811 Review.
Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Allen JE, et al. Among authors: talekar mk. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Oncotarget. 2016. PMID: 27602582 Free PMC article. Review.
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS. Prabhu VV, et al. Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19. Cell Cycle. 2018. PMID: 29157092 Free PMC article.
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.
Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Allen JE, et al. Among authors: talekar mk. Oncotarget. 2021 Oct 12;12(21):2231. doi: 10.18632/oncotarget.28012. eCollection 2021 Oct 12. Oncotarget. 2021. PMID: 34676056 Free PMC article.
Congenital self-healing reticulohistiocytosis.
Lee YH, Talekar MK, Chung CG, Bell MD, Zaenglein AL. Lee YH, et al. J Clin Aesthet Dermatol. 2014 Feb;7(2):49-53. J Clin Aesthet Dermatol. 2014. PMID: 24578781 Free PMC article.
42 results